Wells Fargo lowered the firm’s price target on Kiniksa (KNSA) to $30 from $35 and keeps an Overweight rating on the shares. While abiprubart’s discontinuation came in as a surprise, the firm thinks the new pipeline assets provide upside and further support the company’s commitment to recurrent pericarditis and their cardiovascular franchise.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KNSA:
- Buy Rating for Kiniksa Pharmaceuticals Driven by Strategic Refocus and Commercial Success
- Kiniksa Pharmaceuticals: Strategic Focus on Cardiovascular Growth and Stability Underpins Buy Rating
- Kiniksa Pharmaceuticals Reports Strong ARCALYST Growth
- Kiniksa Pharmaceuticals Ends License Agreement with MedImmune
- Kiniksa reports Q4 EPS (12c), consensus 13c